Jennifer S. Buell: Transforming cancer care through innovation in immuno-oncology
Jennifer S. Buell, President and Chief Executive Officer at MiNK Therapeutics, posted the following on LinkedIn:
“Celebrating Excellence in Science, Manufacturing, and Innovation
A huge congratulations to our incredible CMC (Chemistry, Manufacturing, and Controls) teams at Agenus, MiNK Therapeutics, and SaponiQx and our leader Al Dadson for the transformative achievements in delivering life-saving medicines. Their groundbreaking efforts have driven the success of our state-of-the-art 83,000 sq. ft. CGMP facility in Emeryville, California, a hub of innovation in immuno-oncology.
This advanced facility, equipped with four 2,000L bioreactors, empowers us to efficiently manufacture groundbreaking therapies like Botensilimab, Balstilimab, AgenT-797—a cell therapy leveraging invariant T cells to target and eliminate cancer—and QS-21 Stimulon, a potent adjuvant that enhances vaccine efficacy and immune responses across a range of therapies.
These innovations showcase our dedication to addressing unmet medical needs and offering new hope to patients around the globe.
Thank you to Manufacturing Today for celebrating the transformative work of our teams and sharing our mission to redefine cancer care. Together, we’re creating solutions that save lives and inspire hope.”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023